Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress

I Horvath, S Loukides, T Wodehouse, S A Kharitonov, P J Cole, P J Barnes

Abstract

Background—Bronchiectasis is a chronic inflammatory lung disease associated with increased production of oxidants due mostly to neutrophilic inflammation. Induction of heme oxygenase (HO-1) by reactive oxygen species is a general cytoprotective mechanism against oxidative stress. HO-1 catabolises heme to bilirubin, free iron and carbon monoxide (CO). Exhaled CO measurements may therefore reflect an oxidative stress and be clinically useful in the detection and management of inflammatory lung disorders.

Methods—The levels of exhaled CO of 42 non-smoking patients with bronchiectasis treated or not treated with inhaled corticosteroids were compared with CO levels in 37 normal non-smoking subjects. Results—Levels of exhaled CO were raised in patients with bronchiectasis, both those treated with inhaled corticosteroids (n = 27, median 5.5 ppm, 95% CI 5.16 to 7.76) and those not treated with inhaled corticosteroids (n = 15, median 6.0 ppm, 95% CI 4.74 to 11.8), compared with normal subjects (n = 37, median 3.0 ppm, 95% CI 2.79 to 3.81, p = 0.0024). There was no correlation between exhaled CO and HbCO levels (r = 0.42, p = 0.12) in normal subjects (n = 7), nor between the urine cotinine concentration and exhaled CO levels (r = 0.2, p = 0.12).

Conclusions—Increased levels of exhaled CO may reflect induction of HO-1 and oxidative stress in bronchiectasis. Measurement of exhaled CO may be useful in the management of bronchiectasis and possibly other chronic inflammatory lung disorders.

(Torax 1998;53:867–870)

Keywords: exhaled carbon monoxide; bronchiectasis; heme oxygenase

Oxidative stress and reactive oxygen species have been implicated in the pathogenesis of many pulmonary diseases including chronic inflammatory lung disorders such as asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis. Reactive oxygen species, including the superoxide anion (O₂⁻), hydroxyl radicals, and hydrogen peroxide (H₂O₂), are produced by activated immune and inflammatory cells and cause oxidation of nucleic acids, proteins, and membrane lipids. One of the mechanisms protecting against an oxidative stress is the induction of a stress response protein, heme oxygenase (HO). HO-1, an inducible form of HO, catalyses the degradation of heme to bilirubin, and consequently to the anti-oxidant bilirubin, producing free iron and carbon monoxide (CO) which has several biological activities including stimulation of guanyl cyclase. Some other inflammatory mediators such as cytokines and nitric oxide (NO) are also released during chronic inflammation and are able to induce HO-1 expression.

Exhaled NO levels are raised in patients with bronchiectasis, reflecting the chronic inflammatory process. A vicious circle of microbial colonisation and host derived inflammation leads to damage of adjacent normal lung tissue with neutrophilic infiltration and high levels of proinflammatory cytokines present in airway secretions, resulting in overproduction of O₂⁻ and other oxidants.

We therefore postulated that measurement of CO levels in the breath of patients with bronchiectasis may reflect HO-1 activation and may provide useful information on the control of inflammation and the assessment of new anti-inflammatory treatments.

Methods

Patients

Forty two non-smoking patients (16 men) of mean age 45 (15) years, forced expiratory volume in one second (FEV₁) 59 (19.5)% predicted, carbon monoxide transfer factor (TLCO) 88 (4.4)% predicted with clinically and radiologically diagnosed bronchiectasis confirmed by high resolution computed tomographic (CT) scanning of the thorax were studied. All were clinically stable and had no evidence of acute infective exacerbations for at least four weeks prior to the study. Bronchiectasis was believed to be secondary to tuberculosis in two cases, to primary ciliary dyskinesia in 10, to IgA deficiency in two cases, to a deficiency of a subclass of IgG in three, and with no definite antecedent cause identified in the remaining patients (idiopathic). Patients with cystic fibrosis, allergic bronchopulmonary aspergillosis, asthma, and atopic diseases were excluded. Fifteen patients were taking regular inhaled β₂ agonists and 27 were on inhaled corticosteroids (fluticasone propionate, 500–2000 µg daily). Thirty seven normal non-smoking subjects (20 men) of mean age 33 (17.1) years were free of respiratory infections for at least six weeks before starting the study, had no history of chronic cardiovascular or respiratory disease, and were not receiving any regular medication. These subjects had a negative history of allergy (negative skin prick tests to common allergens), normal spirometric...
values (FEV \textsubscript{1}, 94 (4.9)\% predicted), and normal bronchial reactivity with a provocative concentration of methacholine causing a 20\% fall in FEV \textsubscript{1} (PC\textsubscript{20}) of \geq 32 mg in all subjects.

The subjects were tested by NicCheck I (DynaGe Inc, Cambridge, Massachusetts, USA) which determines the levels of cotinine in urine to ensure non-smoking status. Active and passive smokers (smoke exposure for more than 0.5 hour/day) were excluded from the study. In addition, HbCO was measured in blood in seven normal volunteers and compared with their exhaled CO levels.

The study was approved by the ethics committee of the Royal Brompton Hospital.

MEASUREMENTS

FEV\textsubscript{1} was measured using a dry spirometer (Vitalograph, Buckingham, UK) and the best value of three manoeuvres was expressed as a percentage of the predicted value. Airway responsiveness was measured by methacholine provocation challenge (Dosimeter MB3; MEFAR, Boveza, Italy). The PC\textsubscript{20} was calculated by interpolation of the logarithmic dose-response curve.

Exhaled CO was measured using a modified Micro Smokerlyser (BedfontScientific UK) sensitive to CO from 0 to 500 parts per million (ppm, by volume), adapted for on-line recording of CO concentration and integrated with a chemiluminescence analyser (Model LR2000, Logan Research, UK) to control exhalation parameters. Exhaled CO was not measured on the day of TLCO assessment to exclude the influence of inhaled gas mixture containing 0.3\% CO on exhaled CO levels. The subjects exhaled slowly from functional vital capacity with a constant flow (5–6 l/min) against a low resistance (3 (0.4) mm Hg) over 20–30 s into the analyser. Two successive recordings were made and the highest value was used in all calculations. Ambient CO levels were recorded before the measurements.

STATISTICAL ANALYSIS

The data are presented as medians and ranges. The results of the studied groups were compared by the Mann-Whitney U test and estimates of the differences between groups were expressed as medians and 95\% confidence intervals (CI). Spearman’s rank correlation coefficient was used to test the relationships between variables. A p value of <0.05 was considered significant.

Results

Exhaled CO was detectable in all subjects. The levels of exhaled CO were significantly increased in patients with bronchiectasis (n = 42) compared with healthy subjects (median 6.0 ppm, 95\% CI 5.58 to 8.57 ppm versus median 3.0 ppm, 95\% CI 2.79 to 3.81 ppm, p = 0.0024; fig 1). There was no difference in exhaled CO levels between 27 steroid treated patients and 15 non-treated patients (median 5.5 ppm, 95\% CI –5.16 to 7.76 ppm versus median 6.0 ppm, 95\% CI 4.47 to 11.8 ppm, p = 0.08). There was a tendency for a negative correlation between lung function as assessed by FEV\textsubscript{1} and exhaled CO levels (r = –0.33, p = 0.46; fig 2). There was no correlation between exhaled CO and HbCO levels (r = 0.42, p = 0.12) in normal subjects (n = 7). The urinary levels of cotinine were compared with exhaled CO concentrations in all normal subjects and patients with bronchiectasis and no correlation was found (r = 0.2, p = 0.12).

Discussion

The results of this study show that exhaled CO is increased in patients with bronchiectasis, irrespective of their anti-inflammatory treatment, which might be a reflection of oxidative stress and HO-1 activation.

The source of CO in exhaled air of non-smoking subjects is uncertain. It is likely that exhaled CO derives from an endogenous source since the inhaled HO inhibitor, tin-mesoporphyrin, significantly inhibits the concentration of CO (unpublished observations). The technique used in the present study with a single expiratory manoeuvre against resistance is known to minimise the upper respiratory and ambient air contribution to the exhaled CO.

Bronchiectasis is a chronic inflammatory airway disease which is characterised by neutrophil dominant airway inflammation and damage to bronchial epithelial cells. Increased HO-1 protein expression may be due to the induction of the enzyme by inflammatory cytokines and oxidants such as interleukins, tumour necrosis factor-\alpha, interferon-\gamma, and H\textsubscript{2}O\textsubscript{2} which are capable of inducing HO-1 expression in cell lines and tissues.\textsuperscript{7,8,10} The increase in exhaled CO levels in patients with...
Increased levels of exhaled carbon monoxide in bronchiectasis may be explained by an increased activity of HO-1 expression in the airways of these patients. 

The cellular source of CO in bronchiectasis is not known. Airway macrophages and neutrophils are known to be activated in bronchiectasis and may produce superoxide anions leading to increased HO-1 expression. 

HO-1 may also be induced in various cells in the respiratory tract including epithelial cells and infiltrating inflammatory cells. 

Bacterial infections may contribute to oxidative stress by facilitating the recruitment and activation of phagocytic cells in the lung.

It has been shown that HbCO is strongly related (r = 0.97, p<0.0001) to exhaled CO in smokers in whom HbCO values range from 0 to 15% and exhaled CO from 0 to 100 ppm. 

However, there is no relationship between HbCO values ranging from 0 and 2% and exhaled CO from 0 to 10 ppm which are characteristic of non-smokers. Higher exhaled CO values may be related to more intense inflammation; however, further studies measuring other inflammatory parameters are needed to confirm this hypothesis.

There is some evidence that patients with bronchiectasis treated with inhaled steroids may benefit by a reduction in sputum production and improved lung function. 

However, no inflammatory markers were used in that study to confirm the anti-inflammatory action of steroids. The present study shows that patients with bronchiectasis treated with inhaled steroids tended to have lower levels of exhaled CO than patients not receiving steroids, but the difference was not statistically significant. This observation may be explained by the relative ineffectiveness of steroids on neutrophils, as was recently shown by studies of induced sputum from patients with asthma and COPD.

This study, however, was designed as cross-sectional and cannot clearly demonstrate a causal relationship between steroids and exhaled CO. Controlled studies are needed for that purpose. The lack of a significant effect of inhaled steroid therapy on exhaled CO is in contrast to the reduced levels of exhaled NO in bronchiectasis patients treated with inhaled steroids compared with untreated patients. This may reflect the fact that NO is derived from steroid responsive cells such as epithelial cells and macrophages, rather than from neutrophils.

The effect of increased production of endogenous CO on airway function in patients with bronchiectasis is uncertain. The induction of HO-1 has been suggested to play a part in the antioxidant response. 

By degrading heme and by generating bilirubin, an antioxidant that can scavenge hydroxyl radicals in vitro as efficiently as α-tocopherol, induction of HO-1 may provide an antioxidant protection. CO, a by-product of HO activity, activates guanylate cyclase and is a putative neurotransmitter. 

However, when produced in high concentrations by HO-1, CO may have proinflammatory effects since it is also a potent vasodilator and may increase plasma exudation from airway vessels. Free iron, another end product of HO-1, can act as catalyst in the formation of reactive oxygen species and through this mechanism it may have inflammatory effects. 

However, the latter also induces ferritin expression which may serve to restrict iron from participation in the Fenton reaction, thereby reducing the oxidant burden of the cell. 

The induction of HO-1 has been shown to participate in the resolution of acute inflammation under experimental conditions and it has been suggested that it may play a cytoprotective role in haeme and oxidant-induced cellular injuries. These observations raise the possibility that overexpression of HO-1 may be beneficial in the treatment of chronic inflammatory diseases.

Measurement of exhaled CO, a putative index of HO activity, may be a simple method of detecting and monitoring cytokine mediated inflammation and oxidative stress in the airways of bronchiectasis patients. 

Controlled studies are needed for that purpose. Further studies are needed, however, to relate expired CO levels to the extent of inflammation and to explore this approach in other inflammatory lung diseases.

The authors acknowledge the European Respiratory Society and the Hungarian National Scientific Research Foundation (OTKA-F01 7050), and the British Lung Foundation (UK).


Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress
I Horvath, S Loukides, T Wodehouse, S A Kharitonov, P J Cole and P J Barnes

Thorax 1998 53: 867-870
doi: 10.1136/thx.53.10.867

Updated information and services can be found at:
http://thorax.bmj.com/content/53/10/867

These include:

References
This article cites 21 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/53/10/867#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: respiratory system (526)
Inflammation (1020)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/